摘要Objective:The human cluster of differentiation(CD)300A,a type-Ⅰ transmembrane protein with immunoreceptor tyrosine-based inhibitory motifs,was investigated as a potential immune checkpoint for human natural killer(NK)cells targeting hematologic malignancies(HMs).Methods:We implemented a stimulation system involving the CD300A ligand,phosphatidylserine(PS),exposed to the outer surface of malignant cells.Additionally,we utilized CD300A overexpression,a CD300A blocking system,and a xenotransplantation model to evaluate the impact of CD300A on NK cell efficacy against HMs in in vitro and in vivo settings.Furthermore,we explored the association between CD300A and HM progression in patients.Results:Our findings indicated that PS hampers the function of NK cells.Increased CD300A expression inhibited HM lysis by NK cells.CD300A overexpression shortened the survival of HM-xenografted mice by impairing transplanted NK cells.Blocking PS-CD300A signals with antibodies significantly amplified the expression of lysis function-related proteins and effector cytokines in NK cells,thereby augmenting the ability to lyse HMs.Clinically,heightened CD300A expression correlated with shorter survival and an"exhausted"phenotype of intratumoral NK cells in patients with HMs or solid tumors.Conclusions:These results propose CD300A as a potential target for invigorating NK cell-based treatments against HMs.